Compare Incyte Corporation (INCY) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs M&T Bank Corporation — how do they compare? Incyte Corporation trades at $112.75 (market cap $22.85B), while M&T Bank Corporation trades at $222.43 (market cap $31.42B). The key difference: M&T Bank Corporation is the larger of the two by market cap, and M&T Bank Corporation pays a 2.76% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and M&T Bank Corporation for 100 Days on average.
| INCY | MTB | |
|---|---|---|
Market Cap | $22.85B | $31.42B |
Volume | 1,927,029 | 1,438,219 |
Sector | Health | Financials |
52-Week High | $129.93 | $254.09 |
52-Week Low | $83.80 | $178.63 |
Typical Hold Time | 33 Days | 100 Days |
Enterprise Value | $18.35B | $47.77B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
M&T Bank Corporation (MTB) trades at $216.6, down 0.98% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The bank maintains strong profitability with a 30.85% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights loan growth, AI investments, and a new branch opening, while the company declared a $1.50 dividend payable in September 2026.
The outlook is mixed: analyst consensus is a 'Buy' with a $258.92 price target implying 19.5% upside, but technical weakness and a high proportion of 'Hold' ratings suggest caution. Key risks include volatile cash flows, with a net outflow of $2.01B in 2025, and sensitivity to interest rate changes. Earnings momentum from loan growth and technology investments supports potential recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
